Do you switch therapy to sacituzumab in a patient with metastatic HR+ HER2- breast cancer who has stable systemic disease but new <1cm brain metastasis?

Not necessarily. Particularly, if this is the first CNS lesion that was detected and the patient was able to get definitive SRS therapy. In the ABC 5 guidelines for HER2+ CNS only progression, the committee did not endorse routinely changing therapy after local treatment. A similar argument could be...